Cite
HARVARD Citation
Marine, S. et al. (2020). Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France. Journal of medical economics. pp. 464-473. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Marine, S. et al. (2020). Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France. Journal of medical economics. pp. 464-473. [Online].